KURA Kura Oncology Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: KURA

Price (delayed)

$11.04

Market cap

$982.13M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.37

Enterprise value

$936.34M

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 20

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that ...

Highlights
Kura Oncology's revenue has increased by 8% from the previous quarter but it has decreased by 7% YoY
The gross profit has contracted by 8% YoY but it has grown by 7% from the previous quarter
The equity has plunged by 84% YoY and by 55% from the previous quarter
Kura Oncology's net income has plunged by 51% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.kuraoncology.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of KURA

KURA stock price

How has the Kura Oncology stock price performed over time
Intraday
-5.88%
1 week
-1.43%
1 month
-7.15%
1 year
33.98%
YTD
6.26%
QTD
0.64%

Financial performance

How have Kura Oncology's revenue and profit performed over time
Revenue
$77.23M
Gross profit
$76.66M
Operating income
-$318.09M
Net income
-$296.78M
Gross margin
99.3%
Net margin
-384.3%
The net margin has dropped by 62% year-on-year but it is up by 7% since the previous quarter
KURA's operating margin has dropped by 56% year-on-year but it is up by 7% since the previous quarter
Kura Oncology's net income has plunged by 51% YoY
The company's operating income fell by 45% YoY

Price vs fundamentals

How does KURA's price correlate with its fundamentals

Growth

What is Kura Oncology's growth rate over time

Valuation

What is Kura Oncology stock price valuation
P/E
N/A
P/B
20.24
P/S
12.7
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.12
The company's EPS fell by 49% YoY
The stock's P/B is 144% above its last 4 quarters average of 8.8
The equity has plunged by 84% YoY and by 55% from the previous quarter
The price to sales (P/S) is 24% higher than the last 4 quarters average of 10.9
Kura Oncology's revenue has increased by 8% from the previous quarter but it has decreased by 7% YoY

Efficiency

How efficient is Kura Oncology business performance
The company's return on sales has shrunk by 65% YoY but it rose by 7% QoQ
The return on invested capital has dropped by 61% year-on-year and by 5% since the previous quarter
The ROA has plunged by 53% YoY and by 4.4% from the previous quarter
The return on equity has declined by 46% since the previous quarter

Dividends

What is KURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for KURA.

Financial health

How did Kura Oncology financials performed over time
KURA's total assets is 9% greater than its total liabilities
KURA's total liabilities is up by 43% year-on-year
The quick ratio has contracted by 25% YoY and by 23% from the previous quarter
The debt is 50% smaller than the equity
The debt to equity has surged by 127% since the previous quarter
The equity has plunged by 84% YoY and by 55% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.